The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level

Abstract

Get full access to this article

View all access options for this article.

References

Teunissen

Khalil

. Neurofilaments as biomarkers in multiple sclerosis. Mult Scler 2012; 18: 552–556.

Khalil

Enzinger

Langkammer

. CSF neurofilament and N-acetylaspartate related brain changes in clinically isolated syndrome. Mult Scler 2013; 19: 436–442.

Kuhle

Malmeström

Axelsson

. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis. Acta Neurol Scand 2013; 128: e33–e36.

Gunnarsson

Malmeström

Axelsson

. Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 2011; 69: 83–89.

Axelsson

Malmeström

Gunnarsson

. Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis. Mult Scler 2014; 20: 43–50.

Kuhle

Disanto

Lorscheider

. Fingolimod and CSF neurofilament light chain levels in relapsing–remitting multiple sclerosis. Neurology 2015; 84: 1639–1643.

Petzold

Altintas

Andreoni

. Neurofilament ELISA validation. J Immunol Methods 2010; 352: 23–31.

Gnanapavan

Grant

Morant

. Biomarker report from the phase II lamotrigine trial in secondary progressive MS—neurofilament as a surrogate of disease progression. PloS One 2013; 8: e70019.

Río

Castillό

Rovira

. Measures in the first year of therapy predict the response to interferon beta in MS. Mult Scler 2009; 15: 848–853.

10.

Bielekova

McDermott

. Will CSF biomarkers guide future therapeutic decisions in multiple sclerosis? Neurology 2015; 84: 1620–1621.

11.

Barkhof

Reich

. Can leptomeningeal enhancement be linked to multiple sclerosis? Neurology 2015; 84: 762–763.

The only certain measure of the effectiveness of multiple sclerosis therapy is cerebrospinal neurofilament level—NO

Abstract

Get full access to this article

References